{"prompt": "['Novartis', 'Confidential', 'Page 29', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'Total abstinence (when this is in line with the preferred and usual lifestyle of the', 'subject). Periodic abstinence (e.g., calendar, ovulation, symptom-thermal, post', 'ovulation methods) and withdrawal are not acceptable methods of contraception.', 'Female sterilization (have had surgical bilateral oophorectomy with or without', 'hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking', 'study treatment. In case of oophorectomy alone, only when the reproductive status of', 'the woman has been confirmed by follow up hormone level assessment.', 'Male sterilization (at least 6 months prior to screening). For female subjects on the', 'study, the vasectomized male partner should be the sole partner for that subject.', 'Use of oral, injected or implanted hormonal methods of contraception or other forms', 'of hormonal contraception that have comparable efficacy (failure rate <1%), for', 'example hormone vaginal ring or transdermal hormone contraception.', 'Placement of an intrauterine device (IUD) or intrauterine system (IUS).', 'In case of use of oral contraception, women should have been stable on the same pill for a', 'minimum of 3 months before Visit 201 (Randomization / Start of treatment period).', 'Women are considered post-menopausal and not of child-bearing potential if they have', 'had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile', '(e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral', 'oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In', 'the case of oophorectomy alone, only when the reproductive status of the woman has', 'been confirmed by follow-up hormone level assessment is she considered not of', 'childbearing potential.', '5 Treatment', '5.1', 'Study treatment', '5.1.1 Investigational and control drugs', 'The Investigational treatments are as follows:', 'QVM149 (indacaterol acetate/glycopyronium bromide/MF) 150/50/80 g o.d. delivered', 'as powder in hard capsules via Conceptl', 'QVM149 (indacaterol acetate/glycopyronium bromide/MF) 150/50/160 g o.d. delivered', 'as powder in hard capsules via Conceptl', 'The Comparative treatment is:', 'Open label salmeterol xinafoate /fluticasone propionate 50/500 g b.i.d. delivered as', 'powder via Accuhaler + tiotropium 5 g o.d delivered via Respimat\u00ae', 'Under no circumstances is an alternative inhalation device to be used for the', 'administration of the investigational or reference therapies during the treatment', 'period.QVM149 will be provided as global clinical blinded supplies and will be packed and', 'labeled under the responsibility of Novartis, Drug Supply Management', 'The Comparative treatments, salmeterol xinafoate /fluticasone propionate 50/500 g', 'delivered as powder via Accuhaler + tiotropium 5 g delivered via Respimat\u00ae, will']['Novartis', 'Confidential', 'Page 30', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'either be sourced as local commercial supply by Novartis or provided globally by Novartis', 'as clinical open label supplies.', '5.1.2 Additional treatment', 'Starting with Visit 1 patients will receive short acting beta agonist (salbutamol or albuterol)', 'inhaler to use as rescue medication on an \"as needed\" basis. At Visit 101 patients will also be', 'supplied with open label run-in medication, salmeterol / fluticasone 50/250 g b.i.d. or 50/500', 'g b.i.d. to match their background medication via IRT. It is required for all patients to take', 'the open-label run-in medication, salmeterol / fluticasone twice daily from Visit 101 to Visit', '201. The rescue medication will be provided as needed to the patients for the duration of the', 'study. More details regarding rescue medication are in Section 5.5.6', 'Open-label run in medication, salmeterol xinafoate/fluticasone propionate 50/250 g or', '50/500 g delivered as powder via AccuhalerR will either be sourced as local commercial', 'supply or provided as global clinical open label supplies by Novartis. Salbutamol rescue', 'medication will either be supplied to the investigator sites locally by Novartis or provided by', 'the study center and reimbursed by Novartis.', '5.2 Treatment arms', 'Patients will be randomized to one of the following three treatment arms in a ratio of 1:1:1:', 'QVM149 150/50/80 g o.d. delivered via Conceptl', 'QVM149 150/50/160 g o.d. delivered via Conceptl', 'Salmeterol xinafoate/fluticasone propionate 50/500 g b.i.d. (in the morning and in the', 'evening) delivered via AccuhalerR plus tiotropium 5 g o.d delivered via Respimat\u00ae', '5.3 Treatment assignment and randomization', 'At Visit 201 all eligible patients will be randomized via Interactive Response Technology', '(IRT) to one of the treatment arms. The investigator or his/her delegate will contact the IRT', 'after confirming that the patient fulfills all the inclusion/exclusion criteria. The IRT will', 'assign a randomization number to the patient, which will be used to link the patient to a', 'treatment arm and will specify a unique medication number for the first package of', 'investigational treatment to be dispensed to the patient. The randomization number will not be', 'communicated to the caller.', 'The randomization numbers will be generated using the following procedure to ensure that', 'treatment assignment is unbiased and concealed from patients and investigator staff. A patient', 'randomization list will be produced by the IRT provider using a validated system that', 'automates the random assignment of patient numbers to randomization numbers. These', 'randomization numbers are linked to the different treatment arms, which in turn are linked to', 'medication numbers. A separate medication list will be produced by or under the', 'responsibility of Novartis Drug Supply Management using a validated system that automates', 'the random assignment of medication numbers to packs containing the investigational drug(s).', 'Randomization will be stratified by previous ICS dose of ICS/LABA therapy (medium or', 'high dose) and region.']\n\n###\n\n", "completion": "END"}